Literature DB >> 15477624

Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.

Ging-Yuek R Hsiung1, A Dessa Sadovnick, Howard Feldman.   

Abstract

BACKGROUND: Apolipoprotein E (ApoE) epsilon4 genotype is a well-established risk factor for Alzheimer's disease (AD). However, its effect on predicting conversion from normal to "cognitive impairment, no dementia" (CIND) and from CIND to AD is less clear.
METHODS: We used a nested case-control design from the population-based Canadian Study of Health and Aging (CSHA) to examine the effect of ApoE epsilon4 genotype on the conversion of subjects from normal to CIND and from CIND to AD. We also contrasted these findings with incident cases of AD and vascular dementia (VaD) in the CSHA cohort.
RESULTS: The ApoE epsilon4 genotype was a significant risk factor for conversion from CIND to AD and from normal to AD and VaD. However, it was not a significant risk factor for conversion from normal to CIND. This effect is robust to adjustment for age, sex and education level. There is significant interaction between the ApoE epsilon4 genotype and age for AD and for conversion from CIND to AD. No interaction between ApoE epsilon4 genotype, sex, age, ethnicity and education level was found in other subgroup analyses. The positive predictive value of ApoE epsilon4 for predicting CIND conversion to AD was 0.48, and the negative predictive value was 0.65.
INTERPRETATION: Possession of an ApoE epsilon4 allele increases the risk of AD developing from CIND. It is also associated with a decrease in the age at onset of AD. Its predictive values do not support its utility as a diagnostic test for predicting progression from CIND to AD, but it may be useful in research studies to enrich study samples that have a higher rate of progression to AD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477624      PMCID: PMC522651          DOI: 10.1503/cmaj.1031789

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  27 in total

1.  Apolipoprotein E phenotypes in demented and cognitively impaired patients with and without cerebrovascular disease.

Authors:  L Traykov; A S Rigaud; L Caputo; R Couderc; J Coste; J L Michot; J de Rotrou; P Amouyel; F Forette; F Boller
Journal:  Eur J Neurol       Date:  1999-07       Impact factor: 6.089

Review 2.  A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease.

Authors:  A D Roses
Journal:  Neurogenetics       Date:  1997-05       Impact factor: 2.660

3.  Apolipoprotein E polymorphism and atherosclerosis: insight from a study in octogenarians.

Authors:  J Davignon; D Bouthillier; A C Nestruck; C F Sing
Journal:  Trans Am Clin Climatol Assoc       Date:  1988

4.  The incidence of dementia in Canada. The Canadian Study of Health and Aging Working Group.

Authors: 
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

5.  Modulation by age and gender of risk for Alzheimer's disease and vascular dementia associated with the apolipoprotein E-epsilon4 allele in Latin Americans: findings from the Maracaibo Aging Study.

Authors:  A E Molero; G Pino-Ramírez; G E Maestre
Journal:  Neurosci Lett       Date:  2001-07-06       Impact factor: 3.046

6.  Apolipoprotein E epsilon4 allele is a risk factor for late-onset Alzheimer's disease and vascular dementia in Han Chinese.

Authors:  J G Zhang; J G Yang; Z X Lin; L He; G Y Feng; X Y Ma; C F Wang; P F Lu; S B Song; X Z Dong; D St Clair; G Breen
Journal:  Int J Geriatr Psychiatry       Date:  2001-04       Impact factor: 3.485

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.

Authors:  W J Strittmatter; A M Saunders; D Schmechel; M Pericak-Vance; J Enghild; G S Salvesen; A D Roses
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

9.  Canadian study of health and aging: study methods and prevalence of dementia.

Authors: 
Journal:  CMAJ       Date:  1994-03-15       Impact factor: 8.262

10.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

Authors:  Joan Lindsay; Danielle Laurin; René Verreault; Réjean Hébert; Barbara Helliwell; Gerry B Hill; Ian McDowell
Journal:  Am J Epidemiol       Date:  2002-09-01       Impact factor: 4.897

View more
  43 in total

1.  Incidence of dementia in oldest-old with amnestic MCI and other cognitive impairments.

Authors:  Carrie B Peltz; María M Corrada; Daniel J Berlau; Claudia H Kawas
Journal:  Neurology       Date:  2011-11-09       Impact factor: 9.910

2.  The benefits of apolipoprotein E epsilon4 screening to research.

Authors:  Serge Gauthier
Journal:  CMAJ       Date:  2004-10-12       Impact factor: 8.262

3.  Apolipoprotein E-related all-cause mortality in hospitalized elderly patients.

Authors:  Maria G Matera; Daniele Sancarlo; Francesco Panza; Carolina Gravina; Grazia D'Onofrio; Vincenza Frisardi; Grazia Longo; Luigi P D'Ambrosio; Filomena Addante; Massimiliano Copetti; Vincenzo Solfrizzi; Davide Seripa; Alberto Pilotto
Journal:  Age (Dordr)       Date:  2010-04-20

4.  Interactive effects of apolipoprotein E4 and diabetes risk on later myelinating white matter regions in neurologically healthy older aged adults.

Authors:  Jessica M Foley; David H Salat; Nikki H Stricker; Tyler A Zink; Laura J Grande; Regina E McGlinchey; William P Milberg; Elizabeth C Leritz
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-12-31       Impact factor: 2.035

Review 5.  Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Biochem Pharmacol       Date:  2014-01-04       Impact factor: 5.858

6.  Mild cognitive impairment, incidence, progression, and reversion: findings from a community-based cohort of elderly African Americans.

Authors:  Sujuan Gao; Frederick W Unverzagt; Kathleen S Hall; Kathleen A Lane; Jill R Murrell; Ann M Hake; Valerie Smith-Gamble; Hugh C Hendrie
Journal:  Am J Geriatr Psychiatry       Date:  2013-07-03       Impact factor: 4.105

Review 7.  Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Authors:  Carmen Noelker; Harald Hampel; Richard Dodel
Journal:  Mol Diagn Ther       Date:  2011-04-01       Impact factor: 4.074

8.  Incidence rates of dementia, Alzheimer disease, and vascular dementia in the Japanese American population in Seattle, WA: the Kame Project.

Authors:  Amy R Borenstein; Yougui Wu; James D Bowen; Wayne C McCormick; Jay Uomoto; Susan M McCurry; Gerard D Schellenberg; Eric B Larson
Journal:  Alzheimer Dis Assoc Disord       Date:  2014 Jan-Mar       Impact factor: 2.703

Review 9.  Use of genetic variation as biomarkers for Alzheimer's disease.

Authors:  Christiane Reitz; Richard Mayeux
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

10.  Apolipoprotein ε4-allele as a significant risk factor for conversion from mild cognitive impairment to Alzheimer's disease: a meta-analysis of prospective studies.

Authors:  Ma Fei; Wang Jianhua
Journal:  J Mol Neurosci       Date:  2012-12-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.